FOR INVESTORS
We are the pioneers of optical tissue monitoring.
Founded in 2020, Marginum is revolutionising oncological surgery.
With the developed tissue detection technology for surgery, Marginum aims to make a real impact by helping millions of patients and surgical professionals around the globe.
OVERVIEW
Market forerunner in next-generation surgical techniques
Accurate identification of tumours and distinguishing them from healthy tissues during cancer surgery is a critical challenge surgeons face. With an ageing population and the projected 55 % increase in global cancer incidence by 2040, there will be over 20 million cancer patients each year in need of surgery.
Marginum’s minimally invasive tissue monitoring technology empowers surgeons with precise information about the presence and extent of fluorescent tissue without compromising pre-existent surgical workflow. The patented solution aims to assist surgeons to perform more accurate and targeted resections, reducing tumour recurrence and the need for reoperations while improving patient safety and surgical outcomes.
INVESTOR PERSPECTIVE
“Almaral invests in early-stage biotech and life science companies with technologies that can significantly enhance healthcare professionals’ ability to deliver services with improved efficiency, quality, or significantly reduced costs, without compromising the quality of care. Marginum enables fundamental changes in the surgical market and contributes to solving a global health issue.”
– Dr. Maria SeverinaFounder & CEO, Almaral
“Redstone is a European venture capital firm following selected investment strategies. Redstone’s North Karelia Growth Fund invests in companies that build upon regional strengths in technology and life sciences. Marginum’s promising technology enables positive societal change with safer and more accurate surgery.”
– Kaj HagrosManaging Partner, Redstone Nordics
“Nostetta Ventures invests in early-stage companies with groundbreaking innovations and exceptional teams within North Savo region. Marginum’s industry-shaping technology has its origins in the University of Eastern Finland, and the team excels in surgical technology, clinical research, and rapid advancement of the company’s technology.”
– Noora TuikkaCEO, Nostetta Ventures
GREETINGS FROM OUR CEO
Advancing surgical oncology & patient safety.
“Marginum is developing the next-generation fluorescence-based optical tissue monitoring technology to improve surgical performance and cost-effectiveness. There is an urgent need to decrease healthcare costs and the number of reoperations and complications.
The MARGINUM® tissue monitoring solution assists in safe and efficient tumour detection from surgical suction waste. The surgeon will be notified in near real-time if fluorescence is present in the resected tissue. This non-invasive approach – easily integrated into the current surgical workflow – aims to assist in precise detection of tumour cells leading to minimal damage to healthy tissues.
Our dedicated multidisciplinary team works closely with clinical, academic and industrial leaders to ensure our solutions’ seamless clinical compatibility according to clinicians’ preferences.”
Samu Lehtonen MD
CEO & Co-Founder
OUR PARTNERS
Enabling disruptive innovations
Nostetta Ventures manages North Savo Startup Fund enabling and accelerating the emergence of international growth companies.
Almaral invests in early-stage biotechnology and life science startups providing guidance in risk management, long-term strategies and operational functions.
Redstone is a European venture capital firm managing North Karelia Growth Fund and following selected investment strategies with globally operating teams.
Lynx Financial invests in healthcare and life-science innovations to advance global patient outcomes and medical progress in emerging markets.
The Surgical Innovation Training Laboratory (SITL) at the University of Illinois is one of the world’s leading centres for surgical innovation and research.
Business Finland is a government organisation for trade developing Finland into the most attractive and competitive innovation environment in the world.
University of Eastern Finland is the most multidisciplinary university in Finland ranking among the best in the world in several fields.
MedTech Europe is the European trade association for medical technology, advocating for policy, innovation, sustainability, and patient access.
Centre for Economic Development, Transport and Environment promotes regional competitiveness, well-being and sustainable development.
European Union Structural Funds implement policy programmes to support sustainable growth, development and well-being of the European Union.
OUR MISSION
Marginum’s mission is to pioneer the next-generation tool in surgical techniques and we aspire to be the global leader in surgical tissue monitoring solutions.
We aim to achieve this by developing a groundbreaking fluorescence-based tissue detection system that enables efficient and safe monitoring of tissues during cancer surgery.
Unlike any other solution, Marginum allows precise quantitative detection of fluorescent tissue from surgical suction waste without compromising workflow. With our technology we hope to fulfil our vision to radically improve surgical outcomes and patient welfare, welcoming a data-driven shift in surgical approach.
INVESTOR NEWS RELEASE
Subscribe to our
news releases
Keep up with the insights into Marginum’s pioneering advancements and transformative investment opportunities.
LATEST NEWS & PRESS
-
Marginum Secures U.S. Patent for HIVEN® Detection Technology
Read the article : Marginum Secures U.S. Patent for HIVEN® Detection TechnologyThe United States Patent and Trademark Office (USPTO) has granted Marginum a patent covering key aspects of its fluorescence detection technology.
-
Marginum receives Export2X Internationalisation Award
Read the article : Marginum receives Export2X Internationalisation AwardMarginum has received the 2026 Export2X Internationalisation Award, recognising its rapid growth and expansion into global markets.
-
Marginum signs U.S. Distribution Agreement with ABS Med
Read the article : Marginum signs U.S. Distribution Agreement with ABS MedABS Med has partnered with Marginum to support the planned distribution of HIVEN® across key Midwestern U.S. states, subject to FDA authorisation.
-
Marginum HIVEN® wins Red Dot Product Design Award
Read the article : Marginum HIVEN® wins Red Dot Product Design AwardMarginum wins the prestigious Red Dot Design Award for HIVEN® device, recognising its innovation in advancing cancer surgery through user-centred design.
-
Marginum Launches U.S. Clinical Trial with First Patient Treated
Read the article : Marginum Launches U.S. Clinical Trial with First Patient TreatedMarginum launches a U.S. clinical study with the HIVEN® device at the University of Illinois Hospital & Clinics (UI Health) in Chicago.
-
Strategic distribution partnership with ALMEDA
Read the article : Strategic distribution partnership with ALMEDAALMEDA, a Prague-based medical equipment distributor, has partnered with Marginum to distribute its HIVEN® device in the Czech Republic and Slovakia.
CONTACT
Contact us and learn more about the next steps of our mission.
Location: Kuopio, Finland
Email: info@marginum.com
"*" indicates required fields